Creo Medical Group (LON:CREO) Posts Earnings Results

Creo Medical Group (LON:CREO) issued its quarterly earnings results on Wednesday. The company reported GBX (2) EPS for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%.

Creo Medical Group Stock Performance

CREO opened at GBX 9.80 on Friday. The company has a debt-to-equity ratio of 8.09, a current ratio of 2.79 and a quick ratio of 2.19. The company’s 50 day simple moving average is GBX 12.62 and its two-hundred day simple moving average is GBX 12.82. Creo Medical Group has a 1-year low of GBX 9.50 and a 1-year high of GBX 18.50. The firm has a market capitalization of £47.61 million, a price-to-earnings ratio of 9.80 and a beta of 1.56.

Analyst Ratings Changes

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.